EDLUAR is now commercially available in the United States, according to drug maker Meda Pharmaceuticals Inc, Somerset, NJ. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate and is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep.

“EDLUAR combines the efficacy and safety profile of zolpidem tartrate—an agent used for 17 years—with a new sublingual formulation that is convenient for patients with short-term insomnia whose primary complaint is the inability to fall asleep,” said Harry Sacks, MD, vice president, medical affairs of Meda.

According to Meda, EDLUAR sublingual tablets contain the active ingredient zolpidem tartrate (also the active ingredient in Ambien oral tablets) and have a pharmacokinetic profile characterized by rapid absorption.